Latest News and Press Releases

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod...

Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les...

Dr Falk and Renexxion commit to late-stage development following naronapride’s positive P2b results in gastroparesis, a disease with high unmet need.

Nouscom receives FDA Fast Track Designation for NOUS-209, advancing development of its cancer-prevention immunotherapy for Lynch Syndrome carriers.

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease...

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...

Orphan Drug Designation confers regulatory, financial and strategic advantagesEO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patientsEO2463 has...

UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapyTGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that...

EOM Receives FDA Clearance for Phase 2a Cancer Cachexia Trial

LifeArc partners with Elpida Therapeutics to advance gene therapies for three ultra-rare childhood diseases: SPG50, CLN7 and CMT4J.